| EGAD00001006238 |
In this study, a total of 300 patients with MIBC receiving chemotherapy were included; 62 received NAC before cystectomy and 245 received first-line chemotherapy upon detection of locally-advanced (T4b) or metastatic disease. Treatment response, defined as pathological downstaging (< pTa,CIS,N0) after NAC or complete or partial response after first-line treatment (RECIST criteria). RNA-seq was performed using the QuantSeq kit FWD HT kit (Lexogen) using 500 ng input RNA from 121 tumor samples. Data provided here consist of 780 fastq files for RNA-seq. |
NextSeq 500 |
121 |
| EGAD00001006239 |
In this study, a total of 300 patients with MIBC receiving chemotherapy were included; 62 received NAC before cystectomy and 245 received first-line chemotherapy upon detection of locally-advanced (T4b) or metastatic disease. Treatment response, defined as pathological downstaging (< pTa,CIS,N0) after NAC or complete or partial response after first-line treatment (RECIST criteria). WES was performed using DNA from 165 tumors (76x median coverage) and associated germline DNA (46x median coverage). Data provided here consist of 5,828 fastq files for WES. |
Illumina NovaSeq 6000,NextSeq 500 |
330 |
| EGAD00010001921 |
EPIC array data from 72 tumor samples with muscle invasive bladder cancer. |
EPIC BeadChip (Illumina, San Diego, CA) |
72 |
| EGAD00010001943 |
SNP data from 49 paired samples (tumor/germline) with muscle invasive bladder cancer. |
Illumina Infinium Human Global Screening Array GSAMD-24v2-0_20024620_a1 BeadChip |
98 |
